肿瘤细胞治疗研究
英文原题：Systemic strategies for osteosarcoma: advances and future directions.
Systemic strategies for osteosarcoma: advances and future directions.
尽管手术越来越趋向于保肢，但总体预后仍然充满挑战，局限期疾病的5年生存率为60-70%，而晚期则要低得多。
骨肉瘤是儿童和青少年中常见且具有侵袭性的骨癌，通常影响生长突增期的长骨。治疗包括手术、化疗和放疗的组合。尽管手术已变得更加保肢，但总体预后仍然具有挑战性，局限性疾病的5年生存率为60-70%，晚期则低得多。化疗是主要治疗方法；然而，它可能导致严重的副作用。靶向治疗（如IGF-1R抑制剂、TKIs）和免疫治疗（如检查点抑制剂、CAR-T疗法）是有前景的研究领域，旨在更精确地攻击癌细胞并降低毒性。其他新方法，如基因治疗和药物递送系统，正在探索中。随着持续的研究和新疗法的开发，我们希望在未来显著改善骨肉瘤患者的前景。
Osteosarcoma is a common and aggressive bone cancer in children and adolescents, typically affecting the long bones during growth spurts. Treatment involves a combination of surgery, chemotherapy, and radiotherapy. Although surgery has become more limb-preserving, the overall prognosis remains challenging, with a 5-year survival rate of 60-70% for localized disease and much lower for advanced stages. Chemotherapy is the mainstay treatment; however, it can cause severe side effects. Targeted therapies (e.g., IGF-1R inhibitors, TKIs) and immunotherapy (e.g., checkpoint inhibitors, CAR-T therapies) are promising areas of research that aim to attack cancer cells more precisely with lower toxicity. Other novel approaches, such as gene therapy and drug delivery systems, are being explored. With continued research and development of new therapies, we hope to significantly improve the outlook of patients with osteosarcoma in the future.
MEMBER ACCOUNT
登录成功会直接打开下一页。
